Skip to content

Saturn V Capital Management LP

Follow

13F filer, CIK 1964437, AUSTIN, TX

Saturn V Capital Management LP reported $683,127,656 across 24 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 72.63% of the portfolio.

Accepted , ingested 13F-HR 0001964437-26-000015

Period
2026-09-30
Reported value
$683M
Holdings
24
Top 10 weight
72.63%
New
3
Sold out
2

Largest buys vs the previous quarter

SecurityShares changeApprox. value
VIRadded+1,269,779$14.2M
CELCadded+143,529$11.4M
RAREnew+758,771$11.4M
ANROadded+335,280$8.56M
ERASnew+514,309$7.54M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
IVVDexited-8,392,288-$7.32M
PCVXreduced-80,656-$4.59M
AMLXreduced-152,745-$4.44M
DYNreduced-220,318-$3.55M
JAZZreduced-10,598-$2.45M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001964437-26-000015, largest first. % of portfolio is the value over $683,127,656, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
AMLXAMYLYX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 889,073 shares; 2025Q1: 2,426,436 shares; 2025Q2: 3,260,570 shares; 2025Q3: 4,604,878 shares; 2025Q4: 4,496,487 shares; 2026Q1: 4,349,885 shares; 2026Q2: 4,624,101 shares; 2026Q3: 4,471,356 shares 4,471,356$130M19.05%-152,745Timeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 653,071 shares; 2025Q1: 552,926 shares; 2025Q2: 622,479 shares; 2025Q3: 801,224 shares; 2025Q4: 649,179 shares; 2026Q1: 542,696 shares; 2026Q2: 518,865 shares; 2026Q3: 529,313 shares 529,313$52.4M7.67%+10,448Timeline
IMMXIMMIX BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 2,999,169 shares; 2026Q1: 3,693,585 shares; 2026Q2: 4,658,429 shares; 2026Q3: 4,661,115 shares 4,661,115$48.5M7.1%+2,686Timeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 886,332 shares; 2025Q4: 1,140,033 shares; 2026Q1: 1,201,402 shares; 2026Q2: 1,314,122 shares; 2026Q3: 1,393,956 shares 1,393,956$44.2M6.47%+79,834Timeline
PCVXVAXCYTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 204,285 shares; 2025Q1: 232,295 shares; 2025Q2: 544,221 shares; 2025Q3: 788,441 shares; 2025Q4: 798,940 shares; 2026Q1: 824,532 shares; 2026Q2: 852,914 shares; 2026Q3: 772,258 shares 772,258$43.9M6.43%-80,656Timeline
CELCCELCUITY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,063,783 shares; 2025Q1: 1,093,677 shares; 2025Q2: 1,185,520 shares; 2025Q3: 473,828 shares; 2025Q4: 317,095 shares; 2026Q1: 281,904 shares; 2026Q2: 370,318 shares; 2026Q3: 513,847 shares 513,847$40.9M5.98%+143,529Timeline
IRONDISC MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 509,406 shares; 2025Q1: 518,177 shares; 2025Q2: 396,115 shares; 2025Q3: 340,897 shares; 2025Q4: 298,429 shares; 2026Q1: 449,926 shares; 2026Q2: 524,730 shares; 2026Q3: 612,661 shares 612,661$40.1M5.87%+87,931Timeline
CADLCANDEL THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 2,896,588 shares; 2026Q2: 3,303,686 shares; 2026Q3: 3,476,206 shares 3,476,206$36.3M5.31%+172,520Timeline
JAZZJAZZ PHARMACEUTICALS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 206,952 shares; 2025Q3: 300,610 shares; 2025Q4: 248,070 shares; 2026Q1: 162,961 shares; 2026Q2: 160,938 shares; 2026Q3: 150,340 shares 150,340$34.8M5.1%-10,598Timeline
MNPRMONOPAR THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 155,370 shares; 2025Q4: 325,701 shares; 2026Q1: 345,626 shares; 2026Q2: 311,976 shares; 2026Q3: 312,350 shares 312,350$24.9M3.64%+374Timeline
VIRVIR BIOTECHNOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 770,643 shares; 2026Q3: 2,040,422 shares 2,040,422$22.8M3.34%+1,269,779Timeline
TRVITREVI THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,052,043 shares; 2026Q3: 1,573,876 shares 1,573,876$22.5M3.3%+521,833Timeline
XFORX4 PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 5,800,530 shares; 2026Q1: 6,456,646 shares; 2026Q2: 6,973,343 shares; 2026Q3: 7,366,442 shares 7,366,442$21.4M3.13%+393,099Timeline
ALMSALUMIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 3,135,953 shares; 2026Q1: 3,202,075 shares; 2026Q2: 2,915,443 shares; 2026Q3: 2,855,811 shares 2,855,811$21.1M3.09%-59,632Timeline
SGMTSAGIMET BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,479,918 shares; 2026Q3: 2,002,813 shares 2,002,813$19.8M2.9%+522,895Timeline
DYNDYNE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,455,429 shares; 2025Q3: 2,674,469 shares; 2025Q4: 1,788,616 shares; 2026Q1: 966,609 shares; 2026Q2: 1,057,493 shares; 2026Q3: 837,175 shares 837,175$13.5M1.97%-220,318Timeline
ANROALTO NEUROSCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 88,999 shares; 2026Q2: 182,829 shares; 2026Q3: 518,109 shares 518,109$13.2M1.94%+335,280Timeline
RAREULTRAGENYX PHARMACEUTICAL INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 758,771 shares 758,771$11.4M1.67%newTimeline
ZURAZURA BIO LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 739,960 shares; 2026Q2: 2,101,119 shares; 2026Q3: 2,032,454 shares 2,032,454$8.46M1.24%-68,665Timeline
IKTINHIBIKASE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 3,856,799 shares; 2026Q1: 3,863,445 shares; 2026Q2: 3,869,056 shares; 2026Q3: 3,869,056 shares 3,869,056$7.95M1.16%0Timeline
OCSOCULIS HOLDING AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 516,761 shares; 2026Q1: 516,761 shares; 2026Q2: 684,880 shares; 2026Q3: 847,444 shares 847,444$7.92M1.16%+162,564Timeline
ERASERASCA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 514,309 shares 514,309$7.54M1.1%newTimeline
LTGOLATIGO BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 300,355 shares 300,355$5.02M0.73%newTimeline
MSLESATELLOS BIOSCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 350,000 shares; 2026Q2: 350,000 shares; 2026Q3: 516,800 shares 516,800$4.39M0.64%+166,800Timeline

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
IVVDINVIVYD INC8,392,288$7.32Mshares
OVIDOVID THERAPEUTICS INC663,060$1.78Mshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001964437-26-000015 base2026-11-16